<unk> , sold under the brand name Tygacil, is an tetracycline antibiotic medication for a number of bacterial infections. It is a glycylcycline administered intravenously. It was developed in response to the growing rate of antibiotic resistant bacteria such as Staphylococcus aureus, Acinetobacter baumannii, and E. coli. As a tetracycline derivative antibiotic, its structural modifications has expanded its therapeutic activity to include Gram-positive and Gram-negative organisms, including those of multi-drug resistance. It was given a U.S. Food and Drug Administration (FDA) fast-track approval and was approved on 17 June 2005. It was approved for medical use in the European Union in April 2006. It was removed from the World Health Organization's List of Essential Medicines in 2019. The World Health Organization classifies<unk>  as critically important for human medicine.
Tigecycline
Daptomycin
Linezolid
Telithromycin
Delafloxacin
Teicoplanin
Merafloxacin
Doxycycline